Article
Multidisciplinary Sciences
Isabela Silva de Castro, Giacomo Gorini, Rosemarie Mason, Jason Gorman, Massimiliano Bissa, Mohammad A. Rahman, Anush Arakelyan, Irene Kalisz, Stephen Whitney, Manuel Becerra-Flores, Eric Ni, Kristina Peachman, Hung Trinh, Michael Read, Mei-Hue Liu, Donald Van Ryk, Dominic Paquin-Proulx, Zhanna Shubin, Marina Tuyishime, Jennifer Peele, Mohammed S. Ahmadi, Raffaello Verardi, Juliane Hill, Margaret Beddall, Richard Nguyen, James D. Stamos, Dai Fujikawa, Susie Min, Luca Schifanella, Monica Vaccari, Veronica Galli, Melvin N. Doster, Namal P. M. Liyanage, Sarkis Sarkis, Francesca Caccuri, Celia LaBranche, David C. Montefiori, Georgia D. Tomaras, Xiaoying Shen, Margherita Rosati, Barbara K. Felber, George N. Pavlakis, David J. Venzon, William Magnanelli, Matthew Breed, Josh Kramer, Brandon F. Keele, Michael A. Eller, Claudia Cicala, James Arthos, Guido Ferrari, Leonid Margolis, Marjorie Robert-Guroff, Peter D. Kwong, Mario Roederer, Mangala Rao, Timothy J. Cardozo, Genoveffa Franchini
Summary: SIV vaccines engineered to delete V1 induce V2-specific ADCC, correlating with decreased risk of SIV acquisition, while removal of V1 from HIV envelope immunogens may improve antibody responses to V2 virus vulnerability sites.
Article
Biochemistry & Molecular Biology
Shubbir Ahmed, Tripti Shrivastava, Rajesh Kumar, Mohit Kumar, Manidipa Banerjee, Naresh Kumar, Manish Bansal, Supratik Das, Sweety Samal
Summary: The deletion of glycans from the timer apex of an Indian Glade C origin Env results in a native-like trimeric conformation with improved germ-line antibody accessibility for apex-directed antibodies.This design aspect could be valuable in developing HIV-1 Env-based immunogens for apex-directed antibody induction in immunization studies.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
(2021)
Article
Biochemistry & Molecular Biology
Eric Barklis, Ayna Alfadhli, Jennifer E. Kyle, Lisa M. Bramer, Kent J. Bloodsworth, Robin Lid Barklis, Hans C. Leier, R. Max Petty, Iris D. Zelnik, Thomas O. Metz, Anthony H. Futerman, Fikadu G. Tafesse
Summary: Research shows that CerS2 deficiency alters the lipid composition, specifically inhibiting the receptor binding or fusion of HIV-1 Env during infection.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Cell Biology
Amelia Escolano, Harry B. Gristick, Rajeev Gautam, Andrew T. DeLaitsch, Morgan E. Abernathy, Zhi Yang, Haoqing Wang, Magnus A. G. Hoffmann, Yoshiaki Nishimura, Zijun Wang, Nicholas Koranda, Leesa M. Kakutani, Han Gao, Priyanthi N. P. Gnanapragasam, Henna Raina, Ana Gazumyan, Melissa Cipolla, Thiago Y. Oliveira, Victor Ramos, Darrell J. Irvine, Murillo Silva, Anthony P. West, Jennifer R. Keeffe, Christopher O. Barnes, Michael S. Seaman, Michel C. Nussenzweig, Malcolm A. Martin, Pamela J. Bjorkman
Summary: Sequential immunization using VLPs and increasingly native-like Env-VLPs can elicit heterologous neutralizing antibodies in nonhuman primates, but more potent neutralization is necessary for protection in this animal model against HIV-1 infection. Improving prime-boost regimens to increase bNAb potency and stimulate other immune protection mechanisms is essential for developing anti-HIV-1 vaccines.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Jonathan Richard, Jeremie Prevost, Catherine Bourassa, Nathalie Brassard, Marianne Boutin, Mehdi Benlarbi, Guillaume Goyette, Halima Medjahed, Gabrielle Gendron-Lepage, Fleur Gaudette, Hung-Ching Chen, William D. Tolbert, Amos B. Smith, Marzena Pazgier, Mathieu Dube, Andrew Clark, Walther Mothes, Daniel E. Kaufmann, Andres Finzi
Summary: While HIV-1-mediated CD4 downregulation protects infected cells from ADCC, shed gp120 binds to uninfected bystander CD4+ T cells, sensitizing them to ADCC mediated by HIV+ plasma and triggering a cytokine burst. Temsavir, an HIV-1 attachment inhibitor, not only prevents gp120-CD4 interaction and alters Env antigenicity, but also blocks the immunomodulatory activities of shed gp120. Temsavir protects uninfected bystander CD4+ cells from ADCC responses and cytokine burst by preventing gp120 interaction, reducing shedding, and altering antigenicity.
CELL CHEMICAL BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Peng Zhang, Elisabeth Narayanan, Qingbo Liu, Yaroslav Tsybovsky, Kristin Boswell, Shilei Ding, Zonghui Hu, Dean Follmann, Yin Lin, Huiyi Miao, Hana Schmeisser, Denise Rogers, Samantha Falcone, Sayda M. Elbashir, Vladimir Presnyak, Kapil Bahl, Madhu Prabhakaran, Xuejun Chen, Edward K. Sarfo, David R. Ambrozak, Rajeev Gautam, Malcom A. Martin, Joanna Swerczek, Richard Herbert, Deborah Weiss, Johnathan Misamore, Giuseppe Ciaramella, Sunny Himansu, Guillaume Stewart-Jones, Adrian McDermott, Richard A. Koup, John R. Mascola, Andres Finzi, Andrea Carfi, Anthony S. Fauci, Paolo Lusso
Summary: An mRNA vaccine platform showed promising results in generating broadly neutralizing antibodies in non-human primates and reducing the risk of infection, highlighting its potential for developing an effective HIV-1 vaccine.
Article
Immunology
Harry B. Gristick, Harald Hartweger, Maximilian Loewe, Jelle van Schooten, Victor Ramos, Thiago Y. Oliveira, Yoshiaki Nishimura, Nicholas S. Koranda, Abigail Wall, Kai -Hui Yao, Daniel Poston, Anna Gazumyan, Marie Wiatr, Marcel Horning, Jennifer R. Keeffe, Magnus A. G. Hoffmann, Zhi Yang, Morgan E. Abernathy, Kim-Marie A. Dam, Han Gao, Priyanthi N. P. Gnanapragasam, Leesa M. Kakutani, Ana Jimena Pavlovitch-Bedzyk, Michael S. Seaman, Mark Howarth, Andrew T. Mcguire, Leonidas Stamatatos, Malcolm A. Martin, Anthony P. West Jr, Michel C. Nussenzweig, Pamela J. Bjorkman
Summary: Passive transfer of broadly neutralizing anti-HIV-1 antibodies is a strategy to protect against infection, but eliciting these antibodies through vaccination has been challenging. Researchers have successfully induced CD4 binding site (CD4bs) antibody responses using the antibody IOMA, which has potential as a vaccine strategy to generate broadly neutralizing antibodies against HIV-1.
SCIENCE IMMUNOLOGY
(2023)
Article
Virology
Seth H. Pincus, Megan Stackhouse, Connie Watt, Kelli Ober, Frances M. Cole, Hung-Ching Chen, Amos B. Smith III, Tami Peters
Summary: The reservoir of HIV-infected cells that persist despite anti-retroviral therapy is the main barrier to curing HIV infection. One proposed approach to eliminate these cells is using cytotoxic immunoconjugates targeting the HIV envelope protein. This study explores the effects of different forms of CD4 and a CD4-mimetic molecule on cells expressing the virus's envelope protein.
JOURNAL OF VIROLOGY
(2023)